Stock Ratings / Health Care / TNDM / dividends

BVS (66) NVCR (24) DRTS (33) PRCT (48) ⌘ Pro Terminal →

Tandem Diabetes Care Inc. (TNDM) Dividend Safety Gauge & 10-Year DRIP Compounder

$19.79 +0.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Tandem Diabetes Care Inc. (TNDM) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.38B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TNDM)Realized 20D OHLCV Swing Band: ±11.8%

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TNDM)

✓Walkthrough of TNDM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TNDM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.38%▲ ASCENDING CHANNEL

2026-10-30O $19.42H $19.79L $18.71C $19.79VOL 1.87M

RES: $27.82SUP: $15.59SMA50: $18.02SMA200: $18.93

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TNDM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TNDM Butterfly Map → + Track TNDM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +7.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TNDM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TNDM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TNDM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TNDM)

Health Care Rank #814 of 1016 ⚔️ BVS vs TNDM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TNDM vs. BVS, NVCR, DRTS, PRCT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Tandem Diabetes Care Inc. (TNDM) ranks #814 by composite RQD confidence (35/100, grade D-) and #314 by equity capitalization ($1.38B). Within this direct 5-issuer industry benchmark cohort, BVS leads on earnings valuation at 55.0x trailing P/E, while BVS leads on capital efficiency and profitability with 10.4% ROIC and 68.3% gross margin. BVS currently holds the highest overall quantitative score in the immediate peer group at 66/100 (C+) compared with TNDM at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TNDM ACTIVE Tandem Diabetes Care Inc.	D-	35/100	—	53.8%	-35.0%	+0.56%	$1.38B	Benchmark Subject
BVS Bioventus Inc. (Class A)	C+	66/100	55.0x	68.3%	10.4%	+1.50%	$1.25B	/bvs-vs-tndm →
NVCR NovoCure Limited	E	24/100	—	74.5%	-27.5%	-7.48%	$1.53B	/nvcr-vs-tndm →
DRTS Alpha Tau Medical Ltd.	E	33/100	—	—	-35.0%	-0.90%	$1.22B	/drts-vs-tndm →
PRCT PROCEPT BioRobotics Corporation	D	48/100	—	63.7%	-35.0%	+0.50%	$1.16B	/prct-vs-tndm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001438133

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tandem Diabetes Care Inc. (TNDM) reported GAAP revenue of $1.01B (+7.9% vs. FY2024 revenue of $940.2M , and +35.7% cumulative change since FY2023) , GAAP net income of -$204.7M, operating cash flow of -$9.7M, and free cash flow of -$29.7M (-694.1% YoY). On the balance sheet, TNDM closed FY2025 with $881.1M in total assets against $310.0M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.01B	-$204.7M	-$9.7M	-$29.7M	$881.1M	$310.0M
FY2024 (FY)	2024-12-31	$940.2M	-$96.0M	$24.2M	$5.0M	$967.7M	$308.3M
FY2023 (FY)	2023-12-31	$747.7M	-$222.6M	-$31.8M	-$31.8M	—	—

3. TNDM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TNDM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Tandem Diabetes Care Inc. (NASDAQ: TNDM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $19.79 (+0.56% 1D, market cap $1.38B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TNDM ranks #814 in composite RQD confidence.

How does TNDM compare to BVS and NVCR in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), TNDM carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 53.8%, and ROIC of -35.0%. By comparison, BVS (Bioventus Inc. (Class A)) holds a C+ grade (66/100 RQD, P/E 55.0x, ROIC 10.4%, cap $1.25B) and NVCR (NovoCure Limited) posts a E grade (24/100 RQD, P/E N/A, ROIC -27.5%, cap $1.53B). Among the 5-stock peer group, BVS leads on earnings multiple (55.0x) while BVS leads on capital efficiency (10.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TNDM?

Per TNDM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001438133), Tandem Diabetes Care Inc. generated $1.01B in revenue (+7.9% YoY), -$204.7M in net income, and -$29.7M in free cash flow against $881.1M in total assets and $310.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TNDM trading relative to its 50-day, 200-day, and 52-week technical levels?

TNDM last traded at $19.79 (+0.56% on volume of 3,357,378 shares), positioning the stock +9.82% above its 50-day simple moving average ($18.02) and +4.54% above its 200-day simple moving average ($18.93). Across its 52-week range of $12.26 to $29.65, TNDM sits at the 43.3% percentile with a 14-day RSI of 62.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.8% ($17.45 to $22.13).

TNDM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does TNDM pay a dividend and is it safe?

Tandem Diabetes Care Inc. (TNDM) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: TNDM RQD Cockpit TNDM 12M Forecast TNDM Earnings & Move TNDM Dividends & DRIP TNDM Insiders & 13F TNDM Whale Options TNDM Profit Sankey TNDM News & Why